NeuroBo Pharmaceuticals appoints Marshall H. Woodworth as Acting CFO effective Oct 27, 2023

MetaVia Inc.

Marshall H. Woodworth appointed Acting CFO, Principal Financial and Principal Accounting Officer, effective October 27, 2023.
Woodworth previously served as CFO of Nevakar Inc. (2017-2023), Braeburn Pharmaceuticals, and Furiex Pharmaceuticals.
Compensation: $375 per hour paid to WhiteCap Search Holdings LLC under an engagement agreement; no family relationships or material interests.
Woodworth entered a Proprietary Information and Invention Assignment Agreement with NeuroBo; no other arrangements in connection with appointment.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Marshall H. Woodworth

Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

MTVA · MetaVia Inc.

Effective: 2023-10-27
Filed: October 30, 2023, 7:59 PM ET

On October 25, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of October 27, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Marshall H. Woodworth was appointed as Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer at MetaVia Inc..

Action: appointed
Role: Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer

Exact text from the filing

On October 25, 2023, the Board of Directors (the “Board” ) of NeuroBo Pharmaceuticals, Inc. (the “Company” ) appointed Mr. Marshall H. Woodworth as the Company’s Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, effective as of October 27, 2023.

View on SEC.gov

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-016982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.